Avelumab
- Generic Name
- Avelumab
- Brand Names
- Bavencio
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 1537032-82-8
- Unique Ingredient Identifier
- KXG2PJ551I
- Background
Avelumab is a human IgG1 lambda monoclonal antibody that binds programmed cell death ligand-1 (PD-L1) to block its interaction with its receptors found on T cells and antigen-presenting cells. Avelumab was first approved by the FDA on March 23, 2017. On September 18 and December 18 of the same year, it was also granted approval by EMA and Health Canada, respectively. It is used in the treatment of Merkel cell carcinoma, metastatic urothelial carcinoma, or renal cell carcinoma.
- Indication
Avelumab is indicated for the treatment of adults with metastatic Merkel cell carcinoma (MCC). In the US, it is also used in patients 12 years and older.
It is also indicated as the maintenance treatment in patients with locally advanced or metastatic urothelial carcinoma (UC), which has not progressed with first-line platinum-containing chemotherapy. In the US, avelumab is also indicated to treat locally advanced or metastatic UC with disease progression during or after platinum-containing chemotherapy or within 12 months of neoadjuvant or adjuvant treatment with platinum-containing chemotherapy.
Avelumab is indicated, in combination with axitinib, for the first-line treatment of advanced renal cell carcinoma (RCC).
- Associated Conditions
- Advanced Renal Cell Carcinoma, Metastatic Urothelial Cancer, Locally advanced Urothelial Carcinoma, Metastatic Merkel Cell Carcinoma (MCC)
- Associated Therapies
- First Line Chemotherapy, Maintenance therapy
Avelumab in Combination With Fluorouracil and Mitomycin or Cisplatin and Radiation Therapy in Treating Participants With Muscle-Invasive Bladder Cancer
- Conditions
- Stage II Ureter Cancer AJCC v8Stage II Urethral Cancer AJCC v8Stage III Renal Pelvis Cancer AJCC v8Bladder Carcinoma Infiltrating the Muscle of the Bladder WallStage II Bladder Cancer AJCC v8Stage III Ureter Cancer AJCC v8Stage III Urethral Cancer AJCC v8Urethral Urothelial CarcinomaStage II Renal Pelvis Cancer AJCC v8Stage III Bladder Cancer AJCC v8
- Interventions
- First Posted Date
- 2018-08-07
- Last Posted Date
- 2023-01-06
- Lead Sponsor
- Mayo Clinic
- Target Recruit Count
- 2
- Registration Number
- NCT03617913
- Locations
- 🇺🇸
Mayo Clinic in Arizona, Scottsdale, Arizona, United States
🇺🇸Mayo Clinic, Rochester, Minnesota, United States
🇺🇸Mayo Clinic in Florida, Jacksonville, Florida, United States
Avelumab in the Frontline Treatment of Advanced Classical Hodgkin Lymphoma - a Window Study
- First Posted Date
- 2018-08-06
- Last Posted Date
- 2023-12-12
- Lead Sponsor
- University College, London
- Target Recruit Count
- 49
- Registration Number
- NCT03617666
- Locations
- 🇬🇧
Churchill Hospital, Oxford, United Kingdom
🇬🇧Norfolk and Norwich University Hospital, Norwich, United Kingdom
🇬🇧Derriford Hospital, Plymouth, United Kingdom
Avelumab Combined With Cetuximab and Irinotecan for Treatment Refractory Metastatic Colorectal Microsatellite Stable Cancer
- Conditions
- Interventions
- First Posted Date
- 2018-07-31
- Last Posted Date
- 2020-10-22
- Target Recruit Count
- 59
- Registration Number
- NCT03608046
- Locations
- 🇧🇪
Cliniques Universitaires Saint-Luc, Brussels, Belgium
🇧🇪Grand Hôpital de Charleroi, Charleroi, Belgium
A Combination of Avelumab and Taxane (AVETAX) for Urothelial Cancer
- Conditions
- Interventions
- First Posted Date
- 2018-07-02
- Last Posted Date
- 2023-11-13
- Lead Sponsor
- Yousef Zakharia
- Target Recruit Count
- 21
- Registration Number
- NCT03575013
- Locations
- 🇺🇸
University of Iowa Hospitals and Clinics, Iowa City, Iowa, United States
QUILT-2.024: Phase 2 Neoadjuvant, Consolidation, and Adjuvant Combination NANT Immunotherapy Versus Standard of Care in Subjects With Resectable Non-small Cell Lung Cancer
- Conditions
- Interventions
- First Posted Date
- 2018-07-02
- Last Posted Date
- 2022-04-05
- Lead Sponsor
- ImmunityBio, Inc.
- Registration Number
- NCT03574649
- Locations
- 🇺🇸
Chan Soon-Shiong Institute for Medicine, El Segundo, California, United States
Neoadjuvant Endocrine Therapy, Palbociclib, Avelumab in Estrogen Receptor Positive Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2018-06-29
- Last Posted Date
- 2024-03-27
- Target Recruit Count
- 33
- Registration Number
- NCT03573648
- Locations
- 🇺🇸
Sibley Memorial Hospital, Washington, District of Columbia, United States
🇺🇸Allegheny Health Network, Pittsburgh, Pennsylvania, United States
🇺🇸Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland, United States
Immunotherapy in Combination With Chemotherapy in Small-cell Lung Cancer
- First Posted Date
- 2018-06-26
- Last Posted Date
- 2023-06-02
- Lead Sponsor
- Hellenic Cooperative Oncology Group
- Target Recruit Count
- 55
- Registration Number
- NCT03568097
- Locations
- 🇬🇷
Metropolitan Hospital, Néo Fáliro, Athens, Greece
🇬🇷Patra University Hospital, Río, Patra, Greece
🇬🇷Alexandra Hospital, Athens, Greece
Javelin BRCA/ATM: Avelumab Plus Talazoparib in Patients With BRCA or ATM Mutant Solid Tumors
- Conditions
- Interventions
- First Posted Date
- 2018-06-21
- Last Posted Date
- 2023-09-25
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 202
- Registration Number
- NCT03565991
- Locations
- 🇺🇸
Northside Hospital, Inc. - GCS/Annex, Atlanta, Georgia, United States
🇺🇸Northside Hospital, Inc. - GCS/Northside, Atlanta, Georgia, United States
🇺🇸Atlanta Cancer Care - Atlanta, Atlanta, Georgia, United States
QUILT-3.088: NANT Pancreatic Cancer Vaccine
- Conditions
- Interventions
- Drug: Nab-paclitaxelDrug: GemcitabineDrug: Aldoxorubicin HClBiological: ALT-803Biological: ETBX-011Biological: ETBX-021Biological: ETBX-051Biological: ETBX-061Biological: GI-4000Biological: GI-6207Biological: GI-6301Biological: haNKDrug: AvelumabDrug: BevacizumabDrug: CapecitabineDrug: CyclophosphamideDrug: 5-FluorouracilDrug: LeucovorinDrug: Oxaliplatin
- First Posted Date
- 2018-06-20
- Last Posted Date
- 2021-03-18
- Lead Sponsor
- ImmunityBio, Inc.
- Registration Number
- NCT03563144
- Locations
- 🇺🇸
Chan Soon-Shiong Institute for Medicine, El Segundo, California, United States
QUILT 3.071: NANT Colorectal Cancer (CRC) Vaccine
- Conditions
- Interventions
- Biological: Aldoxorubicin HydrochlorideBiological: ALT-803Biological: ETBX-011Biological: ETBX-021Biological: ETBX-051Biological: ETBX-061Biological: GI-4000Biological: GI-6207Biological: GI-6301Biological: haNKDrug: AvelumabDrug: CapecitabineDrug: CetuximabDrug: CyclophosphamideDrug: 5-FluorouracilDrug: LeucovorinDrug: Nab-paclitaxelDrug: OxaliplatinDrug: RegorafenibProcedure: SBRT
- First Posted Date
- 2018-06-20
- Last Posted Date
- 2024-12-11
- Lead Sponsor
- ImmunityBio, Inc.
- Target Recruit Count
- 2
- Registration Number
- NCT03563157
- Locations
- 🇺🇸
Chan Soon-Shiong Institute for Medicine, El Segundo, California, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.